Æterna Zentaris requests scientific advice from EMA for its phase 3 programme with perifosine in multiple myeloma

Æterna Zentaris requests scientific advice from EMA for its phase 3 programme with perifosine in multiple myeloma
Æterna Zentaris Inc, a late-stage drug development company specialized in oncology and endocrine therapy, has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated phase-3 programmes for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal …

Read more on PharmaBiz